Healthcare · Profile from Healthcare Research Companion
Fresenius Medical Care AG
The world's largest provider of dialysis services and the largest maker of dialysis machines, dialyzers and supplies: a German-listed, US-earning company that was built by joining a family pharmaceutical group's dialysis equipment business to America's biggest dialysis clinic chain in 1996. Its strategy rests on vertical integration ("we make the machines and run the clinics"), roll-up acquisitions approved by antitrust agencies only after divestitures, and a near-total dependence on US Medicare's End-Stage Renal Disease benefit. Its history also includes some of the largest fraud, product-liability and bribery settlements in healthcare, and a 2020s turnaround as patient volumes fell and the parent company Fresenius SE stepped back.
At a glance
- Founded
- September 30, 1996, by combining Fresenius AG's worldwide dialysis business with National Medical Care (NMC), the dialysis unit of W.R. Grace & Co. Roots go back to Fresenius's dialysis products work from the 1960s–70s and to NMC (founded in Boston in 1968)
- Founders
- Fresenius AG (controlled by the Else Kröner-Fresenius Foundation) and W.R. Grace & Co.; NMC was founded by Dr Constantine Hampers and Edward Hager
- Headquarters
- Bad Homburg, Germany; North American headquarters in Waltham, Massachusetts
- Ownership / structure
- Listed in Frankfurt (FME, DAX member for most of its history) and New York (NYSE: FMS, ADRs). AG 1996–2006; partnership limited by shares (AG & Co. KGaA) controlled by Fresenius SE 2006–2023; converted back to an AG on November 30, 2023, ending Fresenius SE's control. Fresenius SE remains the largest shareholder (~32% before March 2025; reduced toward ~25% plus one share in 2025 and further in August 2026; verify current stake)
- Leadership (2026)
- Helen Giza, CEO (since October 2022; previously CFO) and chair of the management board; Martin Fischer, CFO (verify); supervisory board chaired by Michael Sen, CEO of Fresenius SE (verify)
- Segments
- Care Delivery (dialysis clinics and related services, ~80% of revenue), Care Enablement (machines, dialyzers, concentrates, bloodlines, home-dialysis products), and value-based care activities in the US (including the InterWell Health stake)
- Payer and patient
- US Medicare (fee-for-service ESRD prospective payment and, since 2021, Medicare Advantage), Medicaid, US commercial insurers (who pay several times Medicare rates), and public health systems and insurers abroad; patients with end-stage kidney disease who need dialysis three times a week
- Scale
- ~3,601 clinics and ~292,000 patients worldwide at year-end 2025 (down from ~3,925 clinics in 2023); ~109,700 employees; 2025 revenue €19,628m (+2% reported, +8% organic), operating income €1,827m (€2,212m before special items), net income attributable to shareholders €978m (company-reported)
- Capital / market cap
- Funded by operating cash flow, bonds and parent support; market cap peaked at roughly €25–30bn around 2015–2017 and fell below ~€10bn in 2022–23 before partly recovering (reported; verify)
- Signature moves (incl. failures)
- 1996 merger with National Medical Care; 2000 NMC fraud settlement (~$486m); Renal Care Group (2006, ~$4.2bn); Liberty Dialysis (2012, ~$2.1bn); GranuFlo/NaturaLyte settlement (2016, $250m); NxStage home dialysis (2019, ~$2bn); FCPA bribery settlement (2019, ~$231.7m); InterWell Health value-based kidney care merger (2022); AG conversion, FME25 turnaround and divestitures (2023–26)
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1996
Merger with National Medical Care
Merger / founding of Fresenius Medical Care AG
2000
NMC Medicare Fraud Settlement
Regulatory settlement (criminal pleas, civil False Claims Act settlement, corporate integrity agreement)
2006
Renal Care Group Acquisition
Acquisition (with FTC-ordered divestiture)
2012
Liberty Dialysis Acquisition
Acquisition (with FTC-ordered divestiture of 60 clinics)
2016
GranuFlo NaturaLyte Settlement
Product safety notice / FDA Class I recall (2012) and product-liability settlement (2016)
2019
FCPA Bribery Settlement
Regulatory settlement (DOJ non-prosecution agreement and SEC resolution)
2019
NxStage Home Dialysis Acquisition
Acquisition (device company), with FTC-ordered divestiture
2022
InterWell Health Value Based Kidney Care
Three-way merger forming a stand-alone joint venture (Interwell Health); buyout of outside investors in 2025
2023
AG Conversion and FME25 Turnaround
Restructuring (FME25 cost programme and portfolio exits) and governance change (KGaA to AG; deconsolidation from Fresenius SE); CEO change